MC
CORZ icon

Maplelane Capital’s Core Scientific CORZ Stock Holding History

Maplelane Capital’s Portfolio CORZ Stock Details CORZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-54,571
Closed -$767K – 83
2024
Q4 		$767K Buy
+54,571
New +$806K 0.02% 121
2024
Q3 		– Sell
-108,000
Closed -$1M – 80
2024
Q2 		$1M Buy
+108,000
New +$552K 0.03% 81

Other funds holding CORZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
GC
Gullane Capital Memphis, Tennessee $37.4M AUM 112.18% 1-Year Est. Return
OWP
ORG Wealth Partners Dallas, Texas $508M AUM 83.62% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
JCM
JAT Capital Management Greenwich, Connecticut $59.3M AUM 134.04% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HPM
Helix Partners Management New York $374M AUM 136.73% 1-Year Est. Return

Maplelane Capital's CORZ Position: Q1 2025 in Review

Maplelane Capital sold out of Core Scientific (CORZ) in Q1 2025, closing a stake of 54,571 shares — an estimated $767K sold.

Maplelane Capital first reported a position in CORZ in Q2 2024 and held it in 2 quarters. The position peaked at $1M in Q2 2024. 336 funds tracked by Wall St. Rank hold CORZ as of Q1 2025.

  • Maplelane Capital reported no remaining Core Scientific position as of Q1 2025 after selling out during the quarter.
  • Maplelane Capital sold 54,571 Core Scientific shares in Q1 2025, an estimated $767K.
  • Maplelane Capital first reported a position in Core Scientific in Q2 2024 and held it in 2 quarters.
  • Maplelane Capital's Core Scientific position peaked at $1M in Q2 2024.
  • 336 funds tracked by Wall St. Rank held Core Scientific as of Q1 2025.

Based on Maplelane Capital's 13F filing for Q1 2025, filed 15 May 2025.